Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.54 million versus the consensus estimate of $4.94 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.